CD8A and neoplasm: Moreover, IL4I1 induces expression of the inhibitory checkpoint proteins PD-1 and TIM3 on CD8+ T cells upon co-culture with patient-derived tumor organoids (Figure 13) (407), suggesting that IL4I1 inhibitors may need to be combined with immune checkpoint blockade for effective cancer treatment.